Verastem’s 2026 Playbook: AVMAPKI FAKZYNJA CO-PACK Goes Mainline as Cash Runway Extends into 2027

Ticker: VSTM • EPS considerations • revenue forecast context • earnings surprise chatter • EPS consensus whispers as commercialization begins

Overview: a commercial inflection in a KRAS/MAPK portfolio story

Verastem Oncology (Nasdaq: VSTM) issued preliminary, unaudited results for Q4 2025 and the full year, paired with a clear 2026 priorities slate. The core message: a turning point from development to commercialization with AVMAPKI FAKZYNJA CO-PACK driving early revenue and a broader plan to leverage a KRAS G12D program that could, if data cooperate, lift earnings and strategic optionality. For investors who track EPS sentiment or revenue forecasts, today’s release offers a revenue trajectory anchored by a single commercially launched product and a pipeline that could alter the balance of risk and potential in RAS/MAPK-driven cancers.

Key 2025 figures and 2026 horizons

Revenue snapshot: Preliminary, unaudited net product revenues for AVMAPKI FAKZYNJA CO-PACK are about $17.5 million for Q4 2025 and roughly $30.9 million for the full-year 2025. The launch is still in its early chapters, with a focus on geographic and channel expansion into 2026.
Cash runway: As of December 31, 2025, cash, cash equivalents, and investments stood at about $205 million. On a pro forma basis (including net proceeds from exercising expiring cash warrants), cash and investments rise to approximately $234 million, supporting a runway into the first half of 2027.
Warrants: Outstanding cash warrants were exercised, netting about $29.4 million as of January 25, 2026, and no cash exercise warrants remain outstanding. In practical terms: a liquidity event that reduces near-term dilution risk while providing a clearer view of ongoing cash burn vs. revenue generation.
2026 strategic priorities: The company intends to push AVMAPKI FAKZYNJA CO-PACK through commercial milestones and advance VS-7375 (KRAS G12D ON/OFF inhibitor) into multiple KRAS G12D solid tumor indications, building optionality around a differentiated pipeline.
LGSOC pilot data: Self-sustaining LGSOC launch is anticipated in H2 2026, supported by a growing data stream and the ongoing RAMP program family. The focus is on turning a successful launch into sustained operating momentum rather than a one-off event.

2026 Priorities: AVMAPKI FAKZYNJA CO-PACK and the KRAS G12D bet

AVMAPKI FAKZYNJA CO-PACK (avutometinib; defactinib) – the first FDA-approved treatment specifically for adults with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. The program is anchored by the RAMP 301 Phase 3 trial in recurrent LGSOC, with or without a KRAS mutation. Fully enrolled as of December 2025, RAMP 301 is positioned as the confirmatory study for the initial indication and could underpin potential geographic expansion regardless of KRAS mutation status. This is the core commercial engine for 2026 and beyond, and its trajectory will frame the company’s EPS trajectory and potential earnings surprises as the year unfolds.
RAMP 201J data in Japan – The company disclosed updated data from the RAMP201J Phase 2 trial evaluating the AVMAPKI FAKZYNJA CO-PACK combination in LGSOC with or without KRAS mutation. As of January 30, 2026, 16 efficacy-evaluable patients (minimum one post-baseline assessment) had a median follow-up of 10 months. The stated ORR was 38% (6/16). While early and small-sample, the data offer a data point that could influence near-term investor sentiment on KRAS-targeted combinations and inform downstream regulatory and geographic considerations.

Financial context and liquidity tailwinds

The press release frames a company balancing a commercial launch with research-stage momentum. While the document emphasizes preliminary results, the implied revenue forecast for 2026 rests on the continued performance of AVMAPKI FAKZYNJA CO-PACK and the associated commercial footprint. From an EPS and earnings narrative perspective, the absence of explicit EPS data means the market will likely test the durables of profitability as the quarterlies arrive and the LGSOC launch scales.

Key liquidity metrics to watch include: (1) cash burn versus CO-PACK revenue growth, (2) impact of downstream product sales in 2026 on gross margin and operating expenses, and (3) the potential for additional equity or debt actions if clinical milestones pace slower than planned. Analysts may pepper their EPS consensus estimates with scenarios that hinge on the CO-PACK ramp and VS-7375 data cadence, which could produce an earnings surprise if milestones hit earlier than expectations.

Market implications: what this portends for Verastem and peers

Verastem’s transition from a development-stage entity to a commercial-stage company—driven by AVMAPKI FAKZYNJA CO-PACK—is a narrative shared by several biotech peers navigating niche, high-need indications. The company’s 2026 plan hinges on a couple of levers: a successful product launch with a defined patient population and a RAS/MAPK portfolio that could yield optionality beyond LGSOC. If the RAMP 301 data, regulatory outcomes, and geographic expansions align with management’s cadence, the company could begin to unlock a multi-year revenue trajectory that, in turn, tightens the linkage between revenue forecast and EPS trajectory—an area investors will scrutinize as Q4 earnings calls approach.

For sector peers in the KRAS/G12D space and broader RAS/MAPK targets, Verastem’s approach underscores a few themes: (1) the importance of functionally differentiated, FDA-cleared single-agent or combination regimens to sustain a commercial runway, (2) the impact of successful warrant exercises and equity leverage on capital structure during a transition to profitability, and (3) the signal that early-phase data—such as Japan’s ORR readouts—can meaningfully shape near-term equity narratives even when not yet registrational. In short, this is a case study in how a company serially aligns clinical milestones with commercial milestones to potentially deliver a more consistent earnings narrative over time.

Risks and what to watch

The Q4 and full-year numbers are preliminary and unaudited. Actual results may differ as the company closes the books and provides formal 2025 results and 2026 guidance.
Commercial success depends on the speed and geographical reach of AVMAPKI FAKZYNJA CO-PACK adoption, payer dynamics, and competition in KRAS-mutant oncology spaces.
RAMP 301 remains a key catalyst; delays or negative datapoints could temper the implied revenue and EPS progression.
Dependence on one primary product for near-term revenue creates concentration risk; ongoing development of VS-7375 and other programs is essential to diversify the risk profile.

Final take: a 2026 risk-reward curve that could hinge on data cadence

If 2026 unfolds as the company sketches—with AVMAPKI FAKZYNJA CO-PACK scaling and a steady data cadence for RAMP 301 and RAMP201J—the path to a more meaningful EPS footprint could start to resemble a stair-step, not a cliff dive. The warrants’ windfall has already buoyed near-term liquidity, but the real test will be the revenue sustainability and gross margin profile as the LGSOC launch matures. Sector peers watching KRAS/MAPK programs will likely look for similar signals: disciplined cash management, credible commercial expansion plans, and a clear data-led timetable for major milestones. In the world of specialty oncology, the difference between a temporary revenue bump and a durable earnings story is often a handful of pivotal readouts—and a company that can translate them into a growing, predictable revenue forecast and a converging EPS actual versus consensus.